| 2026-05-08 |
详情>>
股本变动：
变动后总股本52668.43万股
|
| 2026-05-08 |
详情>>
业绩披露：
2026年一季报每股收益0.05美元,归母净利润2733.40万美元,同比去年增长2245.53%
|
| 2026-05-06 |
财报披露：
美东时间 2026-05-06 盘后发布财报
|
| 2026-04-28 |
股东大会：
将于2026-06-10召开股东大会
会议内容 ▼▲
- 1.The election of Demetrios L. Kouzoukas, Andrew Toy and Thomas L. Tran as Class II directors, to serve until the 2029 annual meeting of stockholders and until their successors are duly elected and qualified;
2.A non-binding advisory proposal to approve the compensation paid to our named executive officers ("NEOs") for 2025 as disclosed in the attached Proxy Statement (a "Say on Pay" vote);
3.The ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2026;
4.Any other business that may properly come before the Annual Meeting or any postponement or adjournment of the Annual Meeting.
|
| 2026-02-27 |
详情>>
业绩披露：
2023年年报每股收益-0.45美元,归母净利润-2.13亿美元,同比去年增长37.17%
|
| 2026-02-27 |
详情>>
业绩披露：
2025年年报每股收益-0.17美元,归母净利润-8554.9万美元,同比去年增长-98.91%
|
| 2025-11-07 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-0.07美元,归母净利润-3622.9万美元,同比去年增长-73.2%
|
| 2025-08-08 |
详情>>
业绩披露：
2025年中报每股收益-0.02美元,归母净利润-1185.2万美元,同比去年增长-0.77%
|
| 2025-05-09 |
详情>>
业绩披露：
2025年一季报每股收益0.00美元,归母净利润-127.4万美元,同比去年增长93.35%
|
| 2025-04-28 |
股东大会：
将于2025-06-10召开股东大会
会议内容 ▼▲
- 1.The election of Dr. Anna U. Loengard and William G. Robinson, Jr. as Class I directors, to serve until the 2028 annual meeting of stockholders and until their successors are duly elected and qualified;
2.A non-binding advisory proposal to approve the compensation paid to our named executive officers ("NEOs") for 2024 as disclosed in the attached Proxy Statement (a "Say on Pay" vote);
3.The ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2025;
4.Any other business that may properly come before the Annual Meeting or any postponement or adjournment of the Annual Meeting.
|
| 2025-03-03 |
详情>>
业绩披露：
2022年年报每股收益-0.71美元,归母净利润-3.4亿美元,同比去年增长42.23%
|
| 2025-03-03 |
详情>>
业绩披露：
2024年年报每股收益-0.08美元,归母净利润-4300.9万美元,同比去年增长79.84%
|
| 2024-11-08 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.04美元,归母净利润-2091.7万美元,同比去年增长85.36%
|
| 2024-08-08 |
详情>>
业绩披露：
2024年中报每股收益-0.02美元,归母净利润-1176.2万美元,同比去年增长88.40%
|
| 2024-05-07 |
详情>>
业绩披露：
2024年一季报每股收益-0.04美元,归母净利润-1917万美元,同比去年增长73.60%
|
| 2024-04-26 |
股东大会：
将于2024-06-10召开股东大会
会议内容 ▼▲
- 1.The election of Chelsea Clinton, Carladenise Armbrister Edwards and Vivek Garipalli as Class III directors, to serve until the 2027 annual meeting of stockholders and until their successors are duly elected and qualified;
2.A non-binding advisory proposal to approve the compensation paid to our named executive officers ("NEOs") for 2023 as disclosed in the attached Proxy Statement (a "Say on Pay" vote);
3.The ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2024;
4.Any other business that may properly come before the Annual Meeting or any postponement or adjournment of the Annual Meeting.
|
| 2023-07-21 |
股东大会：
将于2023-08-30召开股东大会
会议内容 ▼▲
- 1.A proposal to authorize our Board of Directors (the “Board”) to amend our Amended and Restated Certificate of Incorporation to effect (a) a reverse stock split (the “Reverse Stock Split”) of our outstanding shares of our Class A common stock and Class B common stock at a reverse stock split ratio in the range of 1-for-5 to 1-for-20, and (b) a reduction in the number of authorized shares of our Class A common stock and Class B common stock by a corresponding ratio (the “Authorized Share Reduction”);
2.Any postponement or adjournment of the Special Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies if there are insufficient votes to approve Proposal No. 1 at the time of the Special Meeting (the “Adjournment Proposal”).
|
| 2023-04-26 |
股东大会：
将于2023-06-07召开股东大会
会议内容 ▼▲
- 1.The election of Demetrios L. Kouzoukas and Andrew Toy as Class II directors, to serve until the 2026 annual meeting of stockholders and until their successors are duly elected and qualified;
2.A non-binding advisory proposal to approve the compensation paid to our named executive officers ("NEOs") for 2022 as disclosed in the attached Proxy Statement (a "Say on Pay" vote);
3.The ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2023;
4.Any other business that may properly come before the Annual Meeting or any postponement or adjournment of the Annual Meeting.
|
| 2022-08-12 |
股东大会：
将于2022-09-22召开股东大会
会议内容 ▼▲
- 1.The election of Lee A. Shapiro and William Robinson, Jr. as Class I directors, to serve until the 2025 annual meeting of stockholders and until their successors are duly elected and qualified;
2.A non-binding advisory proposal to determine the frequency with which stockholders will participate in future non-binding advisory votes to approve the compensation of our named executive officers;
3.The ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2022;
4.Any other business that may properly come before the Annual Meeting or any postponement or adjournment of the Annual Meeting.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-01-07 |
详情>>
内部人交易：
Ryans James等共交易3笔
|
| 2020-12-14 |
股东大会：
将于2021-01-06召开股东大会
会议内容 ▼▲
- 1.The BCA Proposal-to consider and vote upon a proposal to approve by ordinary resolution and adopt the Agreement and Plan of Merger, dated as of October 5, 2020 (as amended, the “Merger Agreement”), by and among SCH, Merger Sub and Clover, as amended by that Amendment to the Agreement and Plan of Merger, dated as of December 8, 2020, a copy of which is attached to this proxy statement/prospectus statement as Annex A. The Merger Agreement provides for, among other things, the mergers of (x) Merger Sub with and into Clover, with Clover surviving the merger as a wholly owned subsidiary of SCH, and (y) Clover with and into SCH, with SCH surviving the merger, in each case, in accordance with the terms and subject to the conditions of the Merger Agreement as more fully described elsewhere in this proxy statement/prospectus (the “BCA Proposal”);
2.The Domestication Proposal-to consider and vote upon a proposal to approve by special resolution, the change of SCH’s jurisdiction of incorporation by deregistering as an exempted company in the Cayman Islands and continuing and domesticating as a corporation incorporated under the laws of the State of Delaware (the “Domestication” and, together with the Mergers, the “Business Combination”) (the “Domestication Proposal”);
3.Organizational Documents Proposals-to consider and vote upon the following five separate proposals (collectively, the “Organizational Documents Proposals”) to approve by special resolution, the following material differences between SCH’s Amended and Restated Memorandum and Articles of Association (as may be amended from time to time, the “Cayman Constitutional Documents”) and the proposed new certificate of incorporation (“Proposed Certificate of Incorporation”) and the proposed new bylaws (“Proposed Bylaws”) of Social Capital Hedosophia Holdings Corp. III (a corporation incorporated in the State of Delaware, and the filing with and acceptance by the Secretary of State of Delaware of the certificate of domestication in accordance with Section 388 of the Delaware General Corporation Law (the “DGCL”)), which will be renamed “Clover Health Investments, Corp.” in connection with the Business Combination (SCH after the Domestication and/or the Business Combination, including after such change of name, as applicable, is referred to herein as “Clover Health”):
4.Organizational Documents Proposal A-to authorize the change in the authorized capital stock of SCH from 500,000,000 Class A ordinary shares, par value $0.0001 per share (the “SCH Class A ordinary shares”), 50,000,000 Class B ordinary shares, par value $0.0001 per share (the “Class B ordinary shares” and, together with the Class A ordinary shares, the “ordinary shares”), and 5,000,000 preferred shares, par value $0.0001 per share (the “SCH preferred shares”), to 2,500,000,000 shares of Class A common stock, par value $0.0001 per share, of Clover Health (the “Clover Health Class A common stock”), and 500,000,000 shares of Class B common stock, par value $0.0001 per share, of Clover Health (the “Clover Health Class B common stock”) and 25,000,000 shares of preferred stock, par value $0.0001 per share, of Clover Health (the “Clover Health preferred stock”) (this proposal is referred to herein as “Organizational Documents Proposal A”);
5.Organizational Documents Proposal B-to authorize the board of directors of Clover Health to issue any or all shares of Clover Health preferred stock in one or more classes or series, with such terms and conditions as may be expressly determined by the Board and as may be permitted by the DGCL (this proposal is referred to herein as “Organizational Documents Proposal B”);
6.Organizational Documents Proposal C-to provide that holders of shares of Clover Health Class A common stock will be entitled to cast one vote per share of Clover Health Class A common stock and holders of shares of Clover Health Class B common stock will be entitled to cast 10 votes per share of Clover Health Class B common stock on each matter properly submitted to Clover Health stockholders entitled to vote (this proposal is referred to herein as “Organizational Documents Proposal C”);
7.Organizational Documents Proposal D-to provide that the board of directors of Clover Health be divided into three classes with only one class of directors being elected in each year and each class serving a three-year term (this proposal is referred to herein as “Organizational Documents Proposal D”);
8.Organizational Documents Proposal E-to authorize all other changes in connection with the replacement of the Cayman Constitutional Documents with the Proposed Certificate of Incorporation and Proposed Bylaws as part of the Domestication (copies of which are attached to this proxy statement/prospectus as Annex J and Annex K, respectively), including (1) changing the corporate name from “Social Capital Hedosophia Holdings Corp. III” to “Clover Health Investments, Corp. ” in connection with the Business Combination, (2) making Clover Health’s corporate existence perpetual, (3) adopting Delaware as the exclusive forum for certain stockholder litigation, (4) being subject to the provisions of Section 203 of DGCL and (5) removing certain provisions related to SCH’s status as a blank check company that will no longer be applicable upon consummation of the Business Combination, all of which SCH’s board of directors believes is necessary to adequately address the needs of Clover Health after the Business Combination (this proposal is referred to herein as “Organizational Documents Proposal E”);
9.Director Election Proposal-to consider and vote upon a proposal, assuming the BCA Proposal, the Domestication Proposal and the Organizational Documents Proposals are approved, to elect five directors who, upon consummation of the Business Combination, will be the directors of Clover Health (this proposal is referred to herein as the “Director Election Proposal”);
10.The Stock Issuance Proposal-to consider and vote upon a proposal to approve by ordinary resolution, for purposes of complying with the applicable provisions of Section 312.03 of the NYSE Listed Company Manual, the issuance of shares of Clover Health Class A common stock or Clover Health Class B common stock, as applicable, to (a) the PIPE Investors, including the Sponsor Related PIPE Investors, pursuant to the PIPE Investment and (b) the Clover Stockholders pursuant to the Merger Agreement (this proposal is referred to herein as the “Stock Issuance Proposal”);
11.The Equity Incentive Plan Proposal-to consider and vote upon a proposal to approve by ordinary resolution, the Clover Health 2020 Equity Incentive Plan (this proposal is referred to herein as the “Equity Incentive Plan Proposal”);
12.The Management Incentive Plan Proposal-to consider and vote upon a proposal to approve by ordinary resolution, the Clover Health 2020 Management Incentive Plan (this proposal is referred to herein as the “Management Incentive Plan Proposal”);
13.The ESPP Proposal-to consider and vote upon a proposal to approve by ordinary resolution, the Clover Health 2020 Employee Stock Purchase Plan (this proposal is referred to herein as the “ESPP Proposal”);
14.The Adjournment Proposal-to consider and vote upon a proposal to approve the adjournment of the extraordinary general meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event that there are insufficient votes for the approval of one or more proposals at the extraordinary general meeting (this proposal is referred to herein as the “Adjournment Proposal”).
|